PT Kalbe Farma Tbk is a drug manufacturing company that focuses on prescription pharmaceuticals, over-the-counter drugs, energy drinks, and nutrition products... Show more
Be on the lookout for a price bounce soon.
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where PTKFY advanced for three days, in of 4 cases, the price rose further within the following month. The odds of a continued upward trend are .
The 10-day RSI Indicator for PTKFY moved out of overbought territory on July 08, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 13 similar instances where the indicator moved out of overbought territory. In of the 13 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on July 16, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on PTKFY as a result. In of 22 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for PTKFY turned negative on July 11, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 20 similar instances when the indicator turned negative. In of the 20 cases the stock turned lower in the days that followed. This puts the odds of success at .
PTKFY broke above its upper Bollinger Band on July 02, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.794) is normal, around the industry mean (5.632). P/E Ratio (30.030) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.004). Dividend Yield (0.018) settles around the average of (0.161) among similar stocks. P/S Ratio (3.427) is also within normal values, averaging (3.643).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PTKFY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PTKFY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 81, placing this stock worse than average.
Industry PharmaceuticalsMajor
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
BRWVX | 27.17 | 0.17 | +0.63% |
MFS Blended Research Growth Eq R6 | |||
RGAHX | 82.60 | 0.46 | +0.56% |
American Funds Growth Fund of Amer R5E | |||
EUGCX | 26.00 | 0.14 | +0.54% |
Morgan Stanley Europe Opportunity L | |||
ISIPX | 18.65 | 0.10 | +0.54% |
Voya US Stock Index Port S2 | |||
HSTAX | 103.67 | 0.19 | +0.18% |
Hartford Stock HLS IA |
A.I.dvisor tells us that PTKFY and SNPHF have been poorly correlated (+6% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PTKFY and SNPHF's prices will move in lockstep.
Ticker / NAME | Correlation To PTKFY | 1D Price Change % | ||
---|---|---|---|---|
PTKFY | 100% | N/A | ||
SNPHF - PTKFY | 6% Poorly correlated | N/A | ||
RHHVF - PTKFY | 4% Poorly correlated | -0.09% | ||
RHHBY - PTKFY | 2% Poorly correlated | -0.80% | ||
RHHBF - PTKFY | 1% Poorly correlated | -2.56% | ||
OTSKF - PTKFY | 0% Poorly correlated | N/A | ||
More |